PMID- 33823719
OWN - NLM
STAT- MEDLINE
DCOM- 20211102
LR  - 20220427
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 22
IP  - 16
DP  - 2021 Nov
TI  - Managing dyslipidemia in patients with Type 2 diabetes.
PG  - 2221-2234
LID - 10.1080/14656566.2021.1912734 [doi]
AB  - INTRODUCTION: Type 2 diabetes mellitus (T2DM) is associated with increased risk 
      for atherosclerotic cardiovascular disease (ASCVD) which is partly related to 
      atherogenic dyslipidemia with raised triglycerides, reduced high-density 
      lipoprotein cholesterol levels, and accompanying lipid changes. Treatment of this 
      dyslipidemia is regarded as a priority to reduce the ASCVD risk in T2DM. AREAS 
      COVERED: This article reviews the relevant studies and guidelines from the 
      publications related to this area. EXPERT OPINION: Lifestyle modification should 
      always be encouraged, and statin treatment is indicated in most patients with 
      T2DM based on the outcome of randomized controlled trials. If LDL-C goals are not 
      achieved, first, ezetimibe and subsequently proprotein convertase 
      subtilisin-kexin type 9 (PCSK9) inhibitors should be added. Patients with T2DM 
      derive greater benefits from ezetimibe and PCSK9 inhibitors due to their higher 
      absolute ASCVD risk compared to patients without T2DM. If triglyceride levels 
      remain elevated, a high dose of eicosapentaenoic acid ethyl ester should be 
      added. Fibrates should be used for severe hypertriglyceridemia to prevent acute 
      pancreatitis. Novel treatments including pemafibrate and inclisiran are 
      undergoing cardiovascular outcome trials, and RNA-based therapies may help to 
      target residual hypertriglyceridemia and high lipoprotein(a) with the long acting 
      treatments offering potential improved adherence to therapy.
FAU - Tomlinson, Brian
AU  - Tomlinson B
AUID- ORCID: 0000-0003-3994-2030
AD  - Faculty of Medicine, Macau University of Science and Technology, Macau China.
FAU - Patil, Nivritti Gajanan
AU  - Patil NG
AD  - Faculty of Medicine, Macau University of Science and Technology, Macau China.
FAU - Fok, Manson
AU  - Fok M
AD  - Faculty of Medicine, Macau University of Science and Technology, Macau China.
FAU - Lam, Christopher Wai Kei
AU  - Lam CWK
AUID- ORCID: 0000-0001-6717-5444
AD  - Faculty of Medicine, Macau University of Science and Technology, Macau China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210613
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - EC 3.4.21.- (PCSK9 protein, human)
RN  - EC 3.4.21.- (Proprotein Convertase 9)
SB  - IM
MH  - Acute Disease
MH  - *Anticholesteremic Agents
MH  - *Cardiovascular Diseases
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - *Dyslipidemias/complications/drug therapy
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors
MH  - *Pancreatitis
MH  - Proprotein Convertase 9
OTO - NOTNLM
OT  - Diabetes
OT  - dyslipidemia
OT  - ezetimibe
OT  - fibrates
OT  - icosapent ethyl
OT  - proprotein convertase subtilisin-kexin type 9 inhibitors
OT  - statins
EDAT- 2021/04/08 06:00
MHDA- 2021/11/03 06:00
CRDT- 2021/04/07 05:33
PHST- 2021/04/08 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
PHST- 2021/04/07 05:33 [entrez]
AID - 10.1080/14656566.2021.1912734 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2021 Nov;22(16):2221-2234. doi: 
      10.1080/14656566.2021.1912734. Epub 2021 Jun 13.